| Ytd | 0.30% | |
| 1y | -11.48% |
| Open | 6.28 | Prev Close | 6.50 | Low | 6.25 | High | 6.70 | Mkt Cap | 51.31M |
| Vol | 48.37K | Avg Vol | 11.89K | EPS | -7.60 | P/E | N/A | Forward P/E | -1.43 |
| Beta | 2.36 | Short Ratio | 1.75 | Inst. Own | 6.08% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.88 | 200-d Avg | 6.87 | 1yr Est | 6.50 |
COCH News
Financial Results to Be Released Before Market Open White Bear Lake, Minnesota--(Newsfile Corp. - Oc
Management Will Host a Conference Call at 4:30 P.M. ET on the Same Day White Bear Lake, Minnesota--(
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing heal
White Bear Lake, Minnesota--(Newsfile Corp. - October 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH)
Company Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implante
Company Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implante
Second of Four Planned Modules Moves Rolling FDA Review ForwardAdvances Toward Targeted Completion o
Second of Four Planned Modules Moves Rolling FDA Review Forward Advances Toward Targeted Completion
On October 6, 2026, Envoy Medical, Inc., a Delaware corporation (the "Company"), entered int
Lake Street analyst Frank Takkinen initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy r
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing heal
Canadian and Hong Kong Patents Continue to Strengthen Intellectual Property Protection Across Envoy
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's afte
White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical ® Inc. (NASDAQ: COC
Top Wall Street analysts changed outlook on top names. Baird raised PSN target, BTIG cut WMT target,
HC Wainwright & Co. analyst Yi Chen maintains Envoy Medical (NASDAQ:COCH) with a Buy and lowe
American Bio Medica (OTCMKTS:ABMC - Get Free Report) and Envoy Medical (NASDAQ: COCH - Get Free Repo
Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.07 per share versus the Zacks Consen
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.07) per share which beat the analyst co
Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Repo
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Envoy Medical (NASDAQ:COCH) with
Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a li
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("
Envoy Medical completed three-month visits for all 56 patients in its Acclaim cochlear implant trial
HC Wainwright & Co. analyst Yi Chen reiterates Envoy Medical (NASDAQ:COCH) with a Buy and mai
Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-im
Envoy Medical reported improved 12-month hearing results for its Acclaim cochlear implant as its piv
Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and S
Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and S
Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fu
Termination Reflects Company's Confidence in Current Capital Position White Bear Lake, Minnesota--(N
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a
ustralian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in
Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.08) per share which beat the analyst co
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing heal
Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising
Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Qu
Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Qu
The first three pivotal trial patients implanted at the start of 2025 are now the first to reach the
Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR
Top analysts changed outlook on top names. For full view of changes, see analyst ratings page. Consi
HC Wainwright & Co. analyst Yi Chen initiates coverage on Envoy Medical (NASDAQ:COCH) with a
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.26) per share which beat the analyst co
Envoy Medical completes enrollment for its Acclaim cochlear implant trial, a fully implanted device
Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy
